Lisdexamfetamine dimesylate (Vyvanse) may be marketed for the treatment of binge eating disorder, the FDA said Friday.
It's the first treatment specifically approved for the condition, the agency said.
The drug, previously approved for attention deficit-hyperactivity disorder (ADHD), was shown in two clinical trials to reduce the number of binge episodes and the number of associated behaviors, according to the .
Vyvanse's label for the condition will include an extensive list of potential adverse effects, including rare but life-threatening cardiac abnormalities as well as psychiatric complications. Less severe side effects include jitteriness, constipation, and insomnia.
The drug is an amphetamine stimulant and is currently listed on Schedule II because of its abuse potential.